RESUMO
A backup molecule to compound 2 was sought by targeting the most likely metabolically vulnerable site in this molecule. Compound 18 was subsequently identified as a potent P2X(7) antagonist with very low in vivo clearance and high oral bioavailability in all species examined. Some evidence to support the role of P2X(7) in the etiology of pain is also presented.
Assuntos
Imidazolinas/farmacologia , Antagonistas Purinérgicos/farmacologia , Receptores Purinérgicos P2X7/efeitos dos fármacos , Administração Oral , Animais , Disponibilidade Biológica , Meia-Vida , Haplorrinos , Imidazolinas/administração & dosagem , Imidazolinas/química , Imidazolinas/farmacocinética , Antagonistas Purinérgicos/administração & dosagem , Antagonistas Purinérgicos/química , Antagonistas Purinérgicos/farmacocinética , RatosRESUMO
A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies.